[1] | Siegel, R., D. Naishadham, and A. Jemal, Cancer statistics, 2012. CA: a cancer journal for clinicians, 2012. 62(1): p. 10-29. |
[2] | Beers, M.H., et al., The Merck manual of medical information. 2004: Pocket Books. |
[3] | Sariego, J., Breast cancer in the young patient. The American Surgeon, 2010. 76(12): p. 1397-1400. |
[4] | Anderson, W.F., et al., Male breast cancer: a population- based comparison with female breast cancer. Journal of Clinical Oncology, 2010. 28(2): p. 232-239. |
[5] | Weigelt, B., F.C. Geyer, and J.S. Reis-Filho, Histological types of breast cancer: How special are they? Molecular Oncology, 2010. 4(3): p. 192-208. |
[6] | Weigelt, B., et al., Refinement of breast cancer classification by molecular characterization of histological special types. The Journal of Pathology, 2008. 216(2): p. 141-150. |
[7] | Siegel, R., D. Naishadham, and A. Jemal, Cancer statistics, 2013. CA: a cancer journal for clinicians, 2013. 63(1): p. 11-30. |
[8] | Bhoo Pathy, N., et al., Breast cancer in a multi-ethnic Asian setting: Results from the Singapore–Malaysia hospital-based breast cancer registry. The Breast, 2011. 20, Supplement 2(0): p. S75-S80. |
[9] | Wenzel, L., et al., Defining and measuring reproductive concerns of female cancer survivors. JNCI Monographs, 2005. 2005(34): p. 94-98. |
[10] | Bish, A., et al., Understanding why women delay in seeking help for breast cancer symptoms. Journal of Psychosomatic Research, 2005. 58(4): p. 321-326. |
[11] | Bower, J.E., Behavioral symptoms in patients with breast cancer and survivors. Journal of Clinical Oncology, 2008. 26(5): p. 768-777. |
[12] | Lynch, T.J., Management of malignant pleural effusions. CHEST Journal, 1993. 103(4_Supplement): p. 385S-389S. |
[13] | Davies, C., F. Gleeson, and R. Davies, BTS guidelines for the management of pleural infection. Thorax, 2003. 58(suppl 2): p. ii18-ii28. |
[14] | Lombardi, G., et al., Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis. Cancer Chemother Pharmacol, 2012. 69(3): p. 781-7. |
[15] | Kissane, D.W., et al., Psychological morbidity and quality of life in Australian women with early-stage breast cancer: a cross-sectional survey. The Medical Journal of Australia, 1998. 169(4): p. 192. |
[16] | Boon, H., F. Olatunde, and S. Zick, Trends in complementary/ alternative medicine use by breast cancer survivors: Comparing survey data from 1998 and 2005. BMC Women's Health, 2007. 7(1): p. 4. |
[17] | Wanchai, A., J. Armer, and B. Stewart, Complementary and Alternative Medicine Use Among Women With Breast Cancer: A Systematic Review. Clinical Journal of Oncology Nursing, 2010. 14(4): p. E45-E55. |
[18] | Gerber, B., et al., Complementary and alternative therapeutic approaches in patients with early breast cancer: a systematic review. Breast Cancer Research and Treatment, 2006. 95(3): p. 199-209. |
[19] | Hadi, M.A., et al., Evaluation of breast cancer awareness among female university students in Malaysia. Pharmacy Practice, 2010. 8(1): p. 29-34. |
[20] | Mehnert, A. and U. Koch, Psychological comorbidity and health-related quality of life and its association with awareness, utilization, and need for psychosocial support in a cancer register-based sample of long-term breast cancer survivors. Journal of Psychosomatic Research, 2008. 64(4): p. 383-391. |
[21] | Fentiman, I.S., R.D. Rubens, and J.L. Hayward, A comparison of intracavitary talc and tetracycline for the control of pleural effusions secondary to breast cancer. European Journal of Cancer and Clinical Oncology, 1986. 22(9): p. 1079-1081. |
[22] | Al-Hajj, M., et al., Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences, 2003. 100(7): p. 3983-3988. |
[23] | Light, R.W., Pleural effusion. New England Journal of Medicine, 2002. 346(25): p. 1971-1977. |
[24] | Tan, C., et al., The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. European journal of cardio-thoracic surgery, 2006. 29(5): p. 829-838. |
[25] | Roberts, M.E., et al., Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax, 2010. 65(Suppl 2): p. ii32-ii40. |
[26] | Tremblay, A. and G.t. Michaud, SIngle-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion*. CHEST Journal, 2006. 129(2): p. 362-368. |
[27] | Silver, D.P., et al., Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2010. 28(7): p. 1145-1153. |
[28] | Bear, H.D., et al., Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. Journal of Clinical Oncology, 2006. 24(13): p. 2019-2027. |
[29] | Von Minckwitz, G., et al., Neoadjuvantvinorelbine–capecitabine versus docetaxel–doxorubicin–cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. Journal of the National Cancer Institute, 2008. 100(8): p. 542-551. |
[30] | Martin, M., et al., Adjuvant docetaxel for node-positive breast cancer. New England Journal of Medicine, 2005. 352(22): p. 2302-2313. |